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Abstract 
Background: B-cells are essential in immunity against malaria, but which sub-sets of B-cells specifically recognize 
Plasmodium falciparum and when they appear is still largely unknown.
Results: Using the flow cytometry technique for detection of P. falciparum specific (Pf+) B-cells, this study for the 
first time measured the development of Pf+ B cell (CD19+) phenotypes in Ugandan babies from birth up to nine 
months, and in their mothers. The babies showed increases in Pf+ IgG memory B-cells (MBCs), atypical MBCs, and 
plasma cells/blasts over time, but the proportion of these cells were still lower than in the mothers who displayed 
stable levels (5, 18, and 3%, respectively). Pf+ non-IgG+ MBCs and naïve B-cells binding to P. falciparum antigens were 
higher in the babies compared to the mothers (12 and 50%). In ELISA there was an increase in IgG and IgM antibodies 
over time in babies, and stable levels in mothers. At baby delivery, multigravidae mothers had a higher proportion of 
Pf+ IgG MBCs and less Pf+ naïve B-cells than primigravidae mothers.
Conclusions: In newborns, naïve B-cells are a major player in recognizing P. falciparum. In adults, the high proportion 
of Pf+ atypical MBCs suggests a major role for these cells. Both in infants and adults, non-IgG+ MBCs were higher 
than IgG MBCs, indicating that these cells deserve more focus in future.
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Background
Plasmodium falciparum malaria accounts for over half 
million deaths annually, with children being the most 
affected [1]. Children are the most vulnerable because 
malaria immunity is dependent on age and exposure 
[2, 3]. The blood stage of P. falciparum is responsible 
for most of the malaria-associated pathology. Disease 
symptoms range from fever to more severe complica-
tions, including respiratory distress, metabolic acidosis, 
renal failure, pulmonary edema and cerebral malaria. 
The clinical spectrum of symptomatic disease is caused 
by the asexual blood stages of Plasmodium, where the 
parasite undergoes cyclic replication within human 
erythrocytes [4]. Although the pathogenesis of malaria 
is not completely understood, it is believed to arise 
from the concerted effects of host and parasite factors, 
including the sequestration of infected erythrocytes in 
microvasculature, local and systemic inflammation [5]. 
Naturally acquired immunity is known to require anti-
body responses. The protective role of antibodies in 
combating malaria was first established by passive trans-
fer of immunoglobulin G (IgG) from clinically immune 
adults into children with severe malaria, which rapidly 
attenuated the severity and burden of disease [6]. This 
has been supported by immuno-epidemiological stud-
ies, where antibodies to parasite antigens have been 
found to be associated with protection from clinical epi-
sodes in endemic areas [7–14]. Antibodies may limit the 
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growth of blood-stage parasites and the development of 
clinical symptoms by several known mechanisms. These 
include blocking erythrocyte invasion [15–17], opsonis-
ing parasitized erythrocytes for phagocytic clearance 
[18, 19], monocyte-mediated antibody-dependent cellu-
lar killing [20, 21], and complement-mediated lysis [22], 
and in addition meddling with the adherence of infected 
erythrocytes to vascular endothelium [4]. Inadequate 
production of antibodies to Plasmodium antigens and 
their subsequent loss in the absence of persistent expo-
sure has been proposed to impair B-cell immunologi-
cal memory advancement [4]. Memory B-cells (MBCs) 
play an important role in durable resistance to different 
pathogens by boosting the immune response in times of 
secondary exposure. Studies have shown that antibody 
production can be sustained through re-stimulation of 
MBCs by persistent antigens [23] or by non-prolifer-
ating long lived plasma cells [24, 25]. Protection of the 
adult and the newborn is ensured by antibodies mostly 
of IgG and IgA isotypes. MBCs induced by natural infec-
tion or vaccination correspond to switched MBCs. In the 
peripheral blood, another population of MBCs, called 
IgM memory [26–28] has been described with different 
origin, function and significance. IgM MBCs, also known 
as natural memory or natural effector memory cells [29], 
develop in the absence of germinal centres [30], gener-
ate extra-follicular thymus-independent responses and 
produce natural antibodies [31]. Because of the host 
immature immune system and the antigenic variation 
of the malaria parasite, development of effective B-cells 
and antibody responses occurs after repeated years of 
exposure [32–36]. It has also been speculated that Plas-
modium infection meddles with development and main-
tenance of B-cell memory response [37–41]. There is 
still need to fully understand the development, regula-
tion and maintenance of immunity against malaria [36, 
42, 43]. B-cell phenotypes created amid malaria bouts 
demonstrate the B-cells linked with malaria immunity 
development. Diverse research has portrayed numer-
ous B-cell phenotypes in individuals exposed to differ-
ent malaria episodes [35, 37, 38, 44–49]. Nahrendorf 
et al. [50] showed gradual acquisition of MBCs and anti-
bodies recognizing pre-erythrocytic and cross-stage 
antigens after P. falciparum sporozoite immunization. 
However, the magnitude of these humoral responses 
did not correlate with protection but directly reflected 
parasite exposure in chemoprophylaxis and sporozoite 
immunization. In African youngsters after experiencing 
intense malaria, an expansion in both the total memory 
and transitional B-cell populaces was observed [51]. It is 
important to note that this earlier research studied the 
whole B-cell populace and did not estimate Plasmodium 
falciparum (Pf+) specific B cells. Elispot assay has been 
used to try and find parasite specific cells, for example 
to show that even if antigen-specific antibodies were not 
detected in plasma, antigen-specific B-cells could still 
be found circulating in the blood, suggesting that these 
could be maintained independently of long-lived plasma 
cells [52]. However, Elispot needs activation and sur-
vival of cells for a relatively long time, and compared to 
ELISA-based assays, flow cytometry is a good method for 
estimation of antigen-specific cells. While dealing with 
intricate antigens, flow cytometry has been shown to be 
a better assay option [53]. Malaria calls for flow cytom-
etry analysis since it has a scope of parasite antigens 
that individually have a low number of specific B-cells. 
ELISA-based measures when improved can only quantify 
70% of the response determined by flow cytometry [53]. 
Flow cytometry is advantageous in that there is no need 
of cell incitement thereby expanding the odds of incor-
porating all cells in the reading. In order to acknowledge 
how Pf+ B-cells are actuated and kept up in vivo, these 
cells should be isolated from other B-cells. Here, the flow 
cytometry technique for detection of Pf+  B-cells which 
was developed by Lugaajju et al. [54] was applied to mon-
itor the development of Pf+  B-cell sub-populations in 
newborns from time of birth until 9 months and in their 
respective mothers, in a malaria endemic area.
Methods
Study site and subject enrolment
The study was conducted at Kasangati Health Centre 
(KHC), a referral unit of Wakiso district which is located 
20 km north east of Kampala, the capital city of Uganda. 
The antenatal clinic of KHC is a public charge-free facility 
that runs 5 days a week. On average, 60 patients (20 new 
visits, 40 revisits) are seen per day and about 7 deliveries 
occur daily. In this study area, malaria is meso-endemic 
with peak transmission after the two rainy seasons (Feb-
ruary–March and September–October) every year. The 
study region is peri-urban and over 90% of pregnant 
women attend the antenatal clinic at least once. Between 
March of 2012 to July of 2013, patients were recruited in 
their last trimester from peri-urban villages within 20 km 
from KHC. Eligibility criteria were: Normal deliveries 
with healthy newborns, agreement to come to the study 
clinic for follow up at 10  weeks, 6 and 9  months of the 
child’s age. The selection of the study participants was 
random (patients were selected sequentially as they came 
to the clinic unless they failed the inclusion criteria). As 
policy at KHC, every pregnant woman took at least one 
or two does of IPT during the pregnancy of the delivered 
baby. Also, every pregnant woman was given a long-
lasting insecticide mosquito bed net. During recruit-
ment and follow up visits, a detailed clinical examination 
was performed and the data were entered into the study 
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questionnaire. Malaria rapid diagnostic test (RDT) and 
blood smear examination upon a positive RDT were 
performed.
Sample collection and processing
On the day of baby delivery, 5 to 10 mL of mother’s venous 
blood and the respective umbilical cord blood of the new-
born baby were collected and mixed with lithium heparin 
(BD, Plymouth, UK). At follow-up days, 2 to 4 mL blood 
from babies and 5 to 10 mL from respective mothers (at 
9  months) were collected. Within 4  h after being col-
lected, the blood samples were transported to the Mak-
erere University, Biomedical Cross Cutting Laboratory for 
processing. Peripheral blood mononuclear cells (PBMCs) 
were separated by density gradient centrifugation using 
Ficoll-hypaque (GE HealthCare Bio-Sciences AB, Swe-
den). For this, the blood specimen was diluted with equal 
volume of Dulbecco’s phosphate buffered saline (DPBS, 
Life technologies, Stockholm, Sweden), carefully layered 
over the Ficoll, and centrifuged (400 g) for 30 min at room 
temperature. After centrifugation, plasma was removed 
and stored at −80  °C. The PBMCs were then collected, 
washed twice with DPBS (300 to 400  g for 15  min ×  2) 
to remove Ficoll traces and platelets. The cells were then 
suspended in 1 mL RPMI medium (Sigma, St Louis, MO) 
stained with 0.4% trypan blue (w/v) and counted in a Neu-
berger chamber. The PBMCs were then cryopreserved in 
liquid nitrogen at concentration of 107  cells/mL in heat-
inactivated 90% fetal bovine serum (Sigma, St Louis, MO) 
and 10% DMSO (v/v) (Sigma, St Louis, MO) as previously 
described [55].
Malaria diagnostics
All samples were tested by pLDH/HRP2 rapid diagnostic 
test (RDT) strips (Combo Rapid Diagnostic Test of Pre-
mier Medical Corporation Limited, India) as described 
by Bharti et  al. [56]. Thick blood smears were stained 
with 10% Giemsa dye for 10  min, Plasmodium spp 
blood stage parasites were then counted in microscope 
fields containing at least 200 white blood cells (WBCs). 
The parasitaemia was calculated according to the WHO 
guidelines [57].
Measurement of total anti‑P. falciparum IgG and IgM 
by ELISA
Pf+  total IgG and IgM in blood plasma were measured 
by enzyme linked immune-sorbent assay (ELISA) as 
described [58]. Briefly, microtiter plate wells were coated 
with 1 µg of schizont extract per well (overnight at 4 °C), 
and blocked with 5% skimmed milk (Sigma) for IgG and 
super block dry blend (Thermo Scientific) for IgM for 
2 h at room temperature. Plasma specimens were diluted 
1:200 with plasma dilution buffer (2.5% milk powder 
in phosphate buffered saline with tween 20 plus 0.02% 
sodium azide). Diluted plasma samples were added to 
the wells in quadruplets and incubated in the microtiter 
plates at room temperature for 1 h. The microtiter wells 
were washed 4 times between the incubation (coating, 
blocking, first and secondary antibody) steps. The wells 
were then incubated (45 min) with diluted (1:20,000) per-
oxidase-conjugated goat anti-human IgG/IgM (Sigma) 
and rewashed. Bound secondary antibody was quanti-
fied by adding TMB (3, 3′, 5, 5′-Tetramethylbenzidine) 
substrate (Promega). Optical density (OD) was read at 
450  nm with a reference at 620  nm. Plasma samples of 
Swedish individuals unexposed to P. falciparum infec-
tions were used as negative controls. All specimens were 
analysed twice and the means of the ELISA OD used in 
the analysis.
Plasmodium falciparum ghost infected red blood cells 
(GiRBCs)—carboxyl Qdot conjugation
Red blood cells were infected with the FCR3S1.2 P. fal-
ciparum strain and maintained in  vitro as described 
by Beeson et  al. [59]. The cultures were synchronized 
using 5% D-sorbitol (Sigma) in water. The magneticallly 
enriched trophozoite pellet was treated with streptolysin 
O (Sigma) to obtain GiRBCs as described in Methods in 
Malaria Research [60]. The GiRBC (225  µg) was conju-
gated with 2  nmol carboxyl Qdot (35  µL) using freshly 
prepared 10  mg/mL  N-ethyl-N-dimethylaminopropyl-
carbodiimide as described by Lugaajju et al. [54]. The car-
boxyl Qdot-GiRBC conjugate was diluted 10 times with 
10 mM Borate buffer (pH 7.4) and stored at 4 °C.
Immunophenotyping of P. falciparum specific B‑cells
Immuno-phenotyping of P. falciparum was done accord-
ing to the protocol previously described by Lugaajju et al. 
[54]. Cryopreserved PBMCs (approximately 1  ×  106 
cells) were thawed on ice and washed in cold flow buffer 
(PBS/0.5% BSA/2 mM EDTA). Flow buffer (100 μL) was 
added to each PBMC sample followed by 1 µg Fc block 
(CD16/CD32 mAb, Biolegend) and incubated at 0 to 4 °C 
(on ice water) for 5 min to minimize non-specific bind-
ing and background fluorescence. Carboxyl Qdot-GiRBC 
Conjugate (25  µL) was added, incubated on ice for 
30 min and the cells were re-washed. Eight microliters of 
fluorochrome (FITC)-conjugated mouse anti-human IgG 
monoclonal antibody (mAb, BD Horizon) were added 
and incubated for 30  min to stain 106 cells in 100  µL 
of flow buffer. The cells were then washed and stained 
for 30 min with 3.5 µL each of CD 19 PE CF594, CD20 
V450, and FcRL4 APC fluorochrome-conjugated mouse 
anti-human mAb (BD Horizon). After the staining, 
the cells were washed and re-suspended in 300  µL flow 
buffer. The analysis was done on a LSRII flow cytometer 
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(Becton–Dickinson Immuno Cytometry Systems, San 
Jose, USA). Data was processed using FLOWJO software 
(Tree Star Inc., San Carlos, and Ca, USA).
Statistical analysis
Data analysis was carried out using STATA and Graph 
pad prism. Changes in IgG, IgM levels and Pf+  B-cell 
phenotypes for babies and mothers over time were 
assessed with Wilcoxon rank sum test. The differences 
in medians between two time points were evaluated by 
Mann–Whitney test and non-parametric Kruskal–Wallis 
test was used for comparing more than three time point.
Results
General characteristics of the study population
Healthy newborns (n = 131) and their respective moth-
ers were enrolled into the study. However, during the 
nine months of post-natal follow-up, only 109 mother–
baby pairs fulfilled all the follow-up time points (birth, 
10 weeks, 6 and 9 months) and were included in the sub-
sequent analysis. The mean age of the enrolled mothers 
was 25 years and ranged from 18 to 39 years. Of the 109 
mothers, 27% were primigravidae and 73% mutigravidae. 
The parasitaemia as determined from the samples that 
were RDT positive at the different follow-up time points 
is shown in Table 1.
Development of IgG and IgM antibody responses to P. 
falciparum
To determine the development of plasma IgG and IgM 
antibodies against P. falciparum, schizont extract was 
used in ELISA. The Swedish samples were used as nega-
tive controls and their average antibody OD values for 
IgG (OD = 0.046) and IgM (OD = 0.09), were subtracted 
from the corresponding raw data of Ugandan specimens. 
There was no difference between levels of IgG for mothers 
at delivery and 9 months later. Babies at birth had slightly 
lower levels of Pf+ IgG compared to their mothers. These 
IgG levels in babies decreased even further at 2.5 months, 
and then increased by 6 and 9 months, but were still lower 
than the corresponding levels in their mothers (Fig.  1a). 
Similarly, there was no difference in levels of Pf+ IgM for 
mothers at delivery compared to 9 months later. At birth, 
babies had very low levels of anti-Pf IgM but these lev-
els increased throughout the time points up to 9 months 
even though they did not reach the levels present in their 
mothers (Fig.  1b). In the mothers, there was no correla-
tion between age and antibody titer levels.
Development of P. falciparum specific B‑cell 
sub‑populations
In order to assess the development of different fractions 
of Pf+  B-cells, five B-cell sub-sets were characterized 
from whole peripheral blood collected at the time 
of delivery (M0  =  mother, B0  =  baby at birth), baby 
at 2.5  months (B2.5), baby at 6  months (B6), baby 
and mother at 9  months (B9, M9 respectively). The 
flow cytometry technique for detection of B lympho-
cytes (defined as CD19+  cells) that are Pf+  was used 
to measure the relative proportions of IgG MBCs 
(CD19+CD20+CD27+FcRL4±IgG+), non-IgG+ MBCs 
(CD19+CD20+CD27+FcRL4±IgG−), naïve B-cells 
(CD19+CD20+CD27−FcRL4±IgG−), plasma cells/
blasts (CD19+CD20−CD27+FcRL4±IgG−), and atypi-
cal MBCs (CD19+CD20+CD27−FcRL4±IgG+) as 
shown in Fig. 2. In the mothers, the mean proportions of 
Pf+  IgG MBCs, non-IgG+ MBCs, naïve B-cells, plasma 
cells/blasts and atypical MBCs were 5, 12, 50, 3 and 18% 
respectively. For mothers, there was no significant dif-
ference between the proportions of any of the Pf+ B-cell 
sub-populations at delivery compared to 9 months later. 
For the babies, there was an increase over time in propor-
tions of Pf+ IgG MBCs, non-IgG+ MBCs, plasma cells/
blasts and atypical MBCs. Although the proportions of 
these cells increased, the percentages did not reach adult 
levels for any of them, except for the non-IgG+  MBCs 
where levels were actually higher in the babies com-
pared to the mothers. At birth, the B-cells recognizing 
P. falciparum in the babies were dominated by the naïve 
Table 1 Showing parasitaemia (number of  infected RBC/
µL of  blood) for  mothers and  babies at  different time 
points










Baby at 2.5 months
KB 120 A 9560
Baby at 6 months
KB 56 B 91,760
KB 118 B 22,6240
KB 125B 3840
Baby at 9 months
KB 57 C 5080
Mother at 9 months
KM 91 C 1520
KM 96 C 800
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B-cells. Even though the proportions of Pf+ naïve B-cells 
decreased over time in babies, at 9  months of age the 
ratios of these Pf+  naïve B-cells were still higher in the 
infants compared to the mothers.
Levels of anti‑schizont IgG and IgM in high and low P. 
falciparum specific B‑cell responders
The flow cytometry percentage frequency data for each 
Pf+ CD19+  B-cell sub-population was arranged in 
descending order. The top 10% of the values were consid-
ered the high responders and the lowest 90% of the val-
ues were considered as the low responders. Comparisons 
of the high responders to low responders (lowest 90% of 
values) for the sub-populations of Pf+ CD19+  B-cells 
were made and correlated to the levels of plasma anti—P. 
falciparum IgG and IgM as determined by ELISAs. Those 
that showed significant differences between groups 
of individuals are shown in Figs.  3 and 4 for IgG and 
IgM, respectively. For babies at birth, low proportions 
of Pf+  B-cell sub-populations including FcRL4+non-
IgG+MBCs (CD19+CD20+CD27+FcRL4+IgG−) and 
FcRL4+  naïve B-cells (CD19+CD20+CD27−FcRL4+ 
IgG−) were associated with high levels of schizont spe-
cific plasma IgG, well as high levels of FcRL4−non-
IgG+MBCs (CD19+CD20+CD27+FcRL4−IgG−) were 
associated with high levels of schizont specific plasma 
IgG (Fig.  3a). High levels of FcRL4+IgG MBCs 
(CD19+CD20+CD27+FcRL4+IgG+), FcRL4+  plasma 
cells/blasts (CD19+CD20−CD27+FcRL4+IgG−) and 
FcRL4− plasma cells/blasts (CD19+CD20−CD27+ 
FcRL4−IgG−) were all associated with high levels of 
Pf+ plasma IgG for babies at 6 and 9 months respectively 
(Fig. 3b).
For the mothers, low proportions of Pf+  B-cell 
sub-populations including FcRL4+  non-IgG+MBCs 
(CD19+CD20+CD27+FcRL4+IgG−) (at birth and 9   
months), and FcRL4+IgG MBC (CD19+CD20+CD27+ 
FcRL4+IgG+) at 9  months were associated with high 
levels of Pf+  plasma IgG (Fig.  3c). In addition, high 
proportions of FCRL4− Pf+  atypical MBCs (CD19+ 
CD20+CD27−FcRL4−IgG+), and FCRL4− Pf+  IgGM-
BCs (CD19+CD20+CD27+FcRL4−IgG+) were associ-
ated with high levels of schizont binding plasma IgM for 
babies at birth and mothers at 9  months, respectively. 
However, low levels of FCRL4− Pf+ atypical MBCs were 
associated with high levels of IgM antibodies in mothers 
at 9 months (Fig. 4). Samples from malaria non-endemic 
areas (Swedish donors) showed less than 1% of each pop-
ulation of cells in flow cytometry, and also had very few 
numbers of cells in each subpopulation and hence no cal-
culations could be made for valuable conclusions.
Comparison of mother–baby parasitaemia with antibody 
and B‑cell subpopulations
The respective parasitaemia for both mothers and babies 
at different follow up points were correlated with IgG, IgM 
Elisa ODs and the percentage frequency for each Pf+ spe-
cific CD19+  B-cell subpopulations. The results showed 
that increase in parasitaemia was associated with low IgG 
antibody OD values (p = 0.009). There was no significant 
correlation either between parasitaemia and IgM levels 
or between parasitaemia and the proportions different 
Pf+  specific CD19+  B-cell subpopulations. This could 
largely be due to the small numbers of Pf+ samples (10.7%).
a
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Fig. 1 Development of IgG and IgM antibody responses to Plas-
modium falciparum. The development of IgG and IgM antibodies in 
plasma against P. falciparum schizont extract was analyzed by ELISA 
using plasma specimens of mother–baby pairs (n = 109). The graphs 
show levels of IgG (graph a) and IgM (graph b) in plasma of blood 
collected from babies at birth, 2.5, 6 and 9 months later (see coordi-
nate axis labels B0, B2.5, B6 and B9) and from mothers at delivery and 
9 months later (M0 and M9). There was no difference in the levels of 
IgG and IgM for mothers at birth and 9 months later. At birth, babies 
had lower levels of IgG (a) and IgM (b) as compared to their mothers. 
Levels of IgG and IgM in babies increased over time although they 
did not reach the levels prevailing in the mothers’ blood at 9 months 
after baby delivery. The horizontal lines in the box plots with whiskers 
from minimum to maximum show median levels. Asterisk, double and 
triple asterisks indicate significant differences (p < 0.05, 0.01 and 0.001, 
respectively) between groups as evaluated by Wilcoxon rank sum test
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Fig. 2 Development of Plasmodium falciparum specific B-cell sub-populations. Proportions of Pf+ CD19+B-cell sub-sets in mothers and babies: IgG 
MBCs (a), non-IgG+ MBCs (b), naïve B-cells (c), plasma cells/blasts (d) and atypical MBCs (e) determined using quantum dots flow cytometry. The 
coordinate axes show time points (as in Fig. 1) at which the tested blood specimens were collected
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Fig. 3 Levels of antibodies in IgG ELISA. Measured against schizont extract for individuals that were high responders (HR: top 10% of values) com-
pared to low responders (LR: lowest 90% of values). a Babies at birth, b Babies at 6 and 9 months, c mothers at birth and 9 months later. Markings as 
in Fig. 1
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Comparison of primigravidae and mutigravidae
The study population comprised of primigravidae (27%) 
and mutigravidae (73%) mothers. Prominent differences 
were noted in proportions of Pf+  IgG MBCs and naïve 
B-cells at birth among primigravidae and mutigravidae 
as shown in Fig. 5. Pf+  IgG MBCs were higher in mul-
tigravidae than in primigravidae mothers (p  <  0.05), 
whereas Pf+  naïve B-cells were higher in primigravidae 
compared to in multigravidae (p < 0.05).
Discussion
In this study, a cohort of mothers and their newborn 
babies were recruited and followed up for 9 months after 
baby delivery. The development of plasma antibodies in 
the babies against schizont extract antigens showed a 
pattern that was what could be expected from individu-
als living in an endemic area. Schizont extract was used 
since it contains antigens from merozoites as well as 
other Plasmodium blood stages. The mothers showed 
stable levels of schizont specific IgG and IgM antibodies. 
The newborn babies had parasite specific IgG probably 
transferred through the placenta, followed by a decrease 
and then an increase of the IgG over time as the babies 
were exposed to malaria. This was also accompanied by 
an increase in IgM levels during the follow-up time for 
the babies. Similar results have been found before [61] 
and indicate that the people living in the study area are 
regularly exposed to malaria but also that full immunity 
is not achieved by 9 months of age. The initial antibody 
response to intrauterine  infections in the newborns as 
determined in cord sera is generally of the IgM class [62]. 
In the present study, some infants had high levels of par-
asite specific IgM in the cord blood which suggests that 
they had been  exposed to malaria parasites in utero, as 
was further indicated by one individual who actually had 
parasites in the cord blood. This baby also had a relatively 
high OD-value in IgM ELISA (0.3) compared to others 
at the same time point. The fairly rapid rise in the level 
of IgM as observed in the first 9  months of life reflects 
the primary immune response of the infants towards 
the malaria parasites, among other commonly known 
infections.
In addition, the study investigated the proportions 
of CD19+  Pf+  B-cells. In the mothers, the levels of 
these cells were stable, and showed IgG MBCs, non-
IgG+  MBCs, naïve B-cells, plasma cells/blasts and 
atypical MBCs to be 5, 12, 50, 3 and 18%, respectively. 
In the literature, it has been assumed that IgG MBCs are 
the cells that are of importance for long-term memory 
in the defence against most diseases, but in this present 
study surprisingly high levels of non-IgG+ MBCs posi-
tive for Pf, both in the babies and in the mothers were 
found. These cells were negative for IgG, but most likely 
they could have been positive for IgM since memory 
cells recognizing IgD or IgE at these high levels would 
be unlikely because the total levels of these antibodies 
are normally very low. Moreover, IgA levels in blood 
directed against Pf have previously been shown to be 
very low [63] and sometimes even difficult to detect 
both in maternal and cord blood [64]. Acquisition of 
specific antibody isotypes to Pf antigens has in another 
study been shown to begin with IgM, followed by IgG1 
and IgA [65] and the levels of the latter was shown to be 
detectable only in low levels and to increase not until 
after 9 months of age. IgA directed against Pf has been 
found in breast milk [66] but the levels are usually very 
low in blood [63]. IgM levels, on the other hand, have 
often been shown to be relatively high [67]. It is inter-
esting to note that a relatively large proportion of the 
MBC pool is made up of non-IgG MBC. This is impor-
tant information when trying to understand malaria 
immunity, and which parameters to focus on in vaccine 
studies.

















Fig. 4 Levels of antibodies in IgM ELISA. Measured against schizont 
extract for individuals that were high responders (HR: top 10% of 
values) compared to low responders (LR: lowest 90% of values). Mark-
ings as in Fig. 1





















Fig. 5 Comparison of primigravidae and mutigravidae. Compari-
son of proportions of Pf+ CD19+ IgG MBC and Pf+ naïve B-cells 
between primigravidae and multigravidae at birth. The horizontal lines 
show median levels in the box plots, with  whiskers from minimum to 
maximum. Asterisks indicates significant differences (p < 0.05)
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It was also noted in this study that naïve B-cells binding 
to Pf were found to be at peak in the cord blood, which is 
in line with earlier studies showing naïve cells to be the 
major part of CD19+  response in newborns [68]. But 
even in our adult samples, about half of the cells showed 
binding to Pf which could indicate that in a normal 
immune response, these cells are relatively important. 
This signifies that besides IgG+ MBCs, other memory B 
cells (Pf+ non-IgG+ MBCs) are important in the defense 
against malaria.
In the present study, even though the proportions 
of the B-cell sub-sets increased in babies during the 
9  months after birth, they were still lower than in their 
mothers, indicating that immunity is not yet achieved. 
In the mothers, there was no notable difference in the 
proportions of Pf+  IgG MBCs, non-IgG+ MBCs, atypi-
cal MBCs, plasma cells/blasts, and naïve B-cells at time 
of delivery and 9  months later, suggesting that the pro-
portions of these circulating Pf+ B-cell sub-sets remains 
stable during adulthood. This finding is consistent 
with earlier studies of the whole B-cell pool [69], where 
the number of circulating B-cells remains stable dur-
ing adulthood and it only decreases in individuals older 
than 60 years. Although based on murine models, it has 
been suggested that this is due to a reduced bone marrow 
ability to produce B-cells [70, 71]. In peripheral blood of 
healthy adult donors, human B-cells comprise very low 
numbers of plasma cells (1–3%) [69, 72] which is in line 
with the proportions of Pf+  cells found in the present 
study.
Among the B-cell sub-sets considered in this study, 
the atypical MBCs constituted a relatively large propor-
tion. Individuals living in malaria-endemic areas were 
found with increased levels of atypical MBCs as age 
increased with cumulative Plasmodium exposure [35, 
37, 38]. In this study, atypical MBCs were classified as 
CD19+CD20+CD27−IgG+, and in earlier studies, they 
have been characterized as CD10-CD19+CD20+CD21−
CD27− [45, 73], suggesting that it is the same kind of 
cells. The proportions of atypical MBC has been shown 
to correlate with age and malaria transmission inten-
sity [44, 74] and in the present study, the cells increase 
with age in the babies, but do not reach full adult levels 
during the 9 months of follow-up. Whether these atypi-
cal cells are good or bad for the immune defense is not 
completely clear, but considering the large proportion 
of Pf+  CD19+  cells that they constitute, they must be 
a major player in the development of immunity against 
malaria and they have previously been shown to express 
an array of inhibitory receptors as well as an impaired 
B-cell response [45].
In this study, cells and antibodies circulating in periph-
eral blood were investigated. Ideally, one would like to 
investigate bone marrow, spleen and lymph nodes as well 
to get a full picture of how immunity is formed, especially 
during the first year of life. However, for practical and 
ethical reasons this was not possible. Nevertheless, stud-
ies of peripheral blood cells and antibodies conceivably 
reflect what happens in the rest of the body and provides 
valuable insight.
Despite the fact that many individuals showed very 
low levels of some subpopulations of Pf+  cells, those 
that actually had higher levels of some specific cells 
compared to other individuals were interesting to inves-
tigate further. The study therefore compared the results 
for the high responders (top 10% of values) to the low 
responders (lowest 90% of values) for the subpopulations 
of Pf+  CD19+  B-cells, and also sub-divided the cells 
further into FCRL4+  and FCRL4− cells and correlated 
this to the levels of plasma IgG and IgM determined by 
ELISA. FcRL4 (CD307d) is exclusively present on B-cells 
and previous studies have proposed that FcRL4+ B-cells 
represent a specialized tissue sub-population of MBCs 
[75–78], hence they are capable of eliciting a second-
ary immune response. In order not to miss out on these 
special kind of memory B-cells, FcRL4 marker was 
included in the B-cell phenotyping panel to differenti-
ate the MBCs. High levels of antibodies, especially IgG 
and IgM, have been shown in several previous studies 
to be associated with malaria immunity [11, 79]. In this 
study, the general pattern (Figs.  3 and 4) indicated that 
low proportions of FCRL4+  cells and high proportions 
of FCRL4− cells were associated with high levels of 
IgG or IgM antibodies. This could point towards a situ-
ation where it is better to not have too high a response 
of FCRL4+ cells. The FCRL4 marker has also been indi-
cated to be of importance in HIV, which can induce an 
increase of FCRL4+  cells [80]. Interestingly, both HIV 
and malaria are infections that can persist for a long time 
in the human body (Additional file 1).
The study also compared primigravidae and mutigravi-
dae individuals. It was noted that multigravidae had a 
higher proportion of Pf+  IgG MBCs and lower propor-
tion of Pf+ naïve B-cells, as compared to primigravidae 
at birth. However, after 9  months there was no notable 
difference in the proportions of these cell populations. 
It has been shown before that primigravidae are more 
vulnerable to malaria [81], and from the present study 
results it could be assumed that it is more advantageous 
to have Pf+  IgG MBCs compared to Pf+  naïve B-cells, 
something that is also in line with the general assumption 
of how protective memory against a disease is formed. 
It would have been interesting to investigate presence 
of malaria parasites in placental tissue of all the mothers 
and examine if any correlations occur in factors such as 
pregnancy parity and parasite density. However due to 
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limited resources and the scope of the study, these inves-
tigations could not be carried out.
Conclusions
During the first 9  months of life in a malaria endemic 
area, babies not only develop Pf+ IgG MBCs and plasma 
cells/blasts but they also attain expansion of Pf+  atypi-
cal MBCs and non-IgG+ MBCs. The latter two sub-pop-
ulations of cells occur at relatively high proportions in 
the adult mothers, indicating that traditional MBCs are 
not the only important memory B cells in the process of 
developing immunity against malaria.
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